JUBILANT Stock Analysis

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;padding-top: 25px;;'>JL</div>
Is it time to take in JUBILANT LIFE? JUBILANT LIFE Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The current indifference towards the small price fluctuations of JUBILANT LIFE SCIENCES may raise some interest from investors. The stock closed today at a share price of 0.0 on very low momentum in trading volume. The company directors and management did not add any value to JUBILANT LIFE SCIENCES investors in June. However, most investors can still diversify their portfolios with JUBILANT LIFE SCIENCES to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently very low. The very small Stock volatility is a good signal to investors with longer term investment horizons. Check out Risk vs Return Analysis.

Search Stock Analysis

The JUBILANT LIFE Stock analysis interface makes it easy to digest most current publicly released information about JUBILANT LIFE as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. JUBILANT stock analysis module also helps to analyze JUBILANT LIFE price relationship with some important fundamental indicators such as market cap and management efficiency.

JUBILANT Stock Analysis Notes

The company has price-to-book ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. JUBILANT LIFE SCIENCES has Price/Earnings To Growth (PEG) ratio of 0.7. The entity recorded earning per share (EPS) of 35.53. The firm last dividend was issued on the 12th of September 2018. JUBILANT LIFE had a split on 25th of November 2010. Jubilant Life Sciences Limited manufactures and supplies active pharmaceutical ingredients , solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals, and nutritional products. The company was incorporated in 1978 and is based in Noida, India. JUBILANT LIFE operates under Drug Manufacturers - Major classification in India and is traded on Bombay Stock Exchange. It employs 7700 people. To learn more about JUBILANT call the company at 91 12 0436 1000 or check out http://www.jubl.com.


JUBILANT LIFE is not yet fully synchronised with the market data
JUBILANT LIFE has some characteristics of a very speculative penny stock
JUBILANT LIFE has high likelihood to experience some financial distress in the next 2 years
JUBILANT LIFE has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 69.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate JUBILANT LIFE's market, we take the total number of its shares issued and multiply it by JUBILANT LIFE's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.


The company has Profit Margin (PM) of 6.04 %, which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 14.77 % which suggests for every 100 dollars of sales it generated a net operating income of 0.15.

Management Efficiency

The entity has return on total asset (ROA) of 8.17 % which means that it generated profit of $8.17 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.05 %, meaning that it generated $13.05 on every $100 dollars invested by stockholders. JUBILANT LIFE management efficiency ratios could be used to measure of how well jubilant life sciences is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

JUBILANT LIFE Technical and Predictive Indicators

Did you try this?

Run Global Correlations Now


Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module
Check out Risk vs Return Analysis. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page